沙格列汀与二甲双胍治疗2型糖尿病的临床疗效、安全性分析

Analysis of Clinical Efficacy and Safety of Saxagliptin and Metformin in Treatment of Type 2 Diabetes Mellitus

目的:探讨分析2型糖尿病(type 2 diabetes mellitus,T2DM)患者应用二甲双胍、沙格列汀治疗的临床疗效,并评估用药方案的安全性。方法:随机抽取2015年8月至2016年7月期间于公安县中医医院实施治疗的T2DM患者104例作对照研究,按照随机数字表法,将患者分为两组,其中B组(n=52例)患者采用二甲双胍,而A组(n=52例)患者采用沙格列汀,探讨两组患者所采用的治疗方式应用于2型患者的临床疗效和安全性。结果:A组临床疗效明显比B组好(P<0.05);A组安全性与B组相比无明显差异(P>0.05);两组患者干预前FBG、HbA_(lc)、2h PG相比无明显差异(P>0.05),干预后FBG、Hb A_(lc)、2h PG均优于治疗前(P<0.05),组间干预后相比,A组FBG、HbA_(lc)、2h PG均低于B组(P<0.05)。结论:临床上针对T2D M患者,应用沙格列汀治疗的整体疗效较为理想,并且,在安全性方面也优于二甲双胍。因此,临床应用价值较高。

Objective：To explore and analyze the clinical effects of Saxagliptin and Metformin in treatment of patients with T2 DM,and to evaluate the safety of the drug regimen.Methods：104 patients with T2 DM who were treated in Gongan County Chinese Medicine Hospital from August 2015 to July 2016 were randomly collected.And according to the random number table method,the patients were divided into two groups.In the B group（n=52 cases）,patients were treated with metformin,while in the A group（n=52 cases）,patients were treated with Saxagliptin.Then,the clinical efficacy and safety of the two groups of patients in the treatment of patients with T2 DM were evaluated.Results：The clinical effect in the A group was significantly higher than that of B group（P〈0.05）;There was no significant difference in the security between the B group and the A group（P〉0.05）;There was no significant difference in the comparison of FBG,HbAlc,2h PG of two groups of patients before intervention（P〉0.05）,and the FBG,HbAlc,2h PG after intervention were better than those before treatment（P〈0.05）.After intervention,the FBG,HbAlc,and 2hPG in the A group were lower than those of B group（P〈0.05）.Conclusion：For patients with T2 DM in the clinical,the overall efficacy of Saxagliptin is more ideal,and in terms of safety,it is better than metformin.Therefore,the clinical application value of it is high.